|
0
|
|
A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions.
(nature.com)
|
De Coster W
…
Rademakers R
Nature Genetics
2026-04-01
|
#sequencing
#neurodegeneration
#dementia
#repeat expansion
#genome-wide association
|
|
0
|
|
eIF3 musketeers: loyal in health, rogue in disease, and redeemed by therapeutic targeting.
(link.springer.com)
|
Mohammadinejad R
…
Wolf DA
The EMBO Journal
2026-04-01
|
#infection
#translation
#cancer
#therapeutics
#neurodegeneration
|
|
0
|
|
Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis.
(nature.com)
|
Hop PJ
…
Veldink JH
Nature Genetics
2026-04-01
|
#sequencing
#variants
#neurodegeneration
#genetics
|
|
0
|
|
ALS mutations disrupt self-association between the ubiquilin STI1 hydrophobic groove and internal placeholder sequences.
(link.springer.com)
|
Onwunma J
…
Wohlever ML
The EMBO Journal
2026-04-01
|
#neurodegeneration
#phase separation
#proteostasis
#chaperone
|
|
0
|
|
Human hippocampal neurogenesis in adulthood, ageing and Alzheimer's disease.
(nature.com)
|
Disouky A
…
Lazarov O
Nature
2026-04-01
|
#transcriptomics
#chromatin
#single-cell
#neurodegeneration
#neurogenesis
|
|
0
|
|
Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease.
(nature.com)
|
Cummings JL
…
Vradenburg G
Nature Medicine
2026-04-01
|
#prevention
#therapeutics
#neurodegeneration
#biomarker
|
|
0
|
|
LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.
(nature.com)
|
Mabrouk OS
…
Graham DL
Nature Medicine
2026-04-01
|
#clinical trial
#pharmacodynamics
#neurodegeneration
#antisense
#neuropathology
|